Background Thrombolytic agents used clinically rely on the activation of plasminogen to plasmin. Plasmin possesses multiple actions including increasing thrombin activity and activation of platelets. Thus, after successful thrombolytic therapy, arterial hyperactivity and reocclusion may be the result of a predominant plasmin-induced thrombogenic action at the site of the residual thrombus. Fibrolase, a direct-acting fibrinolytic enzyme from southern copperhead snake venom, induces rapid clot lysis in vitro. Fibrolase does not rely on plasminogen activation or any other bloodborne components for activity and is not inhibited by any of the rapidly acting serine proteinase inhibitors in blood.
Methods and Results
We investigated the efficacy of fibrolase to lyse an occlusive thrombus formed in the carotid artery of the anesthetized dog. Electrolytic injury was initiated in both the right and left carotid arteries. Thirty minutes after both arteries were occluded, each vessel was infused with either fibrolase (4 mg/kg over 5 minutes) or physiological saline (over 5 minutes). In two separate groups of dogs, anisoylated plasminogen streptokinase activator complex (APSAC) (0.1 U/kg) was infused into the occluded vessel. In the artery infused with fibrolase, five of five dogs exhibited espite the clinical efficacy of currently used D thrombolytic agents, excessive bleeding as well as the failure to achieve rapid and complete clot lysis have provided the stimulus to search for a more optimal means of achieving thrombolysis.
Thrombolytic agents in current clinical use activate plasminogen, leading to the formation of plasmin, a serine proteinase.1 Plasmin, in addition to degrading fibrin and facilitating clot lysis, may actually lead to platelet activation and promote a thrombogenic state at the site of the original occlusive lesion.2-6 Thrombin activity, as determined by the increase in the plasma concentration of fibrinopeptide A, a peptide cleaved from fibrinogen by thrombin, increases in patients given recombinant tissue-type plasminogen activator (rt-PA) or streptokinase (SK).7-9 The plasmin-induced increase c) 1994 American Heart Association, Inc. patency within 6±1 minutes of the infusion (P<.05 versus vehicle-treated artery; Fisher's exact test). In the contralateral carotid artery that received vehicle, the occlusion was maintained throughout the experimental protocol. APSAC alone lysed the thrombus in each vessel within 17±3 minutes. Five minutes after the end of fibrolase administration and in one of the groups administered APSAC, a glycoprotein (GP)IIb/IIIa antibody, 7E3 (0.8 mg/kg IV), was administered to prevent reocclusion of the patent artery. After 7E3 administration, the vessel treated with fibrolase remained patent in four of five dogs, and six of six APSAC-treated vessels were patent for the remainder of the observation period (2 hours) .
Conclusions These studies demonstrate that local administration of fibrolase lyses a carotid arterial thrombus rapidly without excessive hemorrhage or hemodynamic compromise. The enzyme in combination with antiplatelet therapy (7E3) offers a unique mechanism for clot dissolution and may prove useful as a clinically efficacious alternative to presently used thrombolytic agents or may act in a synergistic manner with plasminogen activators. (Circulation. 1994; 90:2448 -2456 Key Words * thrombolysis * antibodies * plasminogen in thrombus-associated thrombin leads to platelet aggregation at the site of the residual thrombus and may, in concert with other factors, contribute to coronary artery reocclusion after successful thrombolysis.2,4 Platelet activation and aggregation in the region of a residual thrombus may be important contributing factors to thrombus formation and vessel reocclusion. 10 The inherent plasmin-related deficiencies of clinically available thrombolytic agents provide the impetus to examine alternative approaches and develop improved lytic agents with the goals of enhancing the incidence of recanalization, preventing reocclusion, and reducing the frequency of bleeding complications.11
In view of the potential limitations of plasminogen activator-based thrombolytic agents, we have chosen to investigate the thrombolytic activity of a fibrinolytic enzyme purified from the southern copperhead snake (Agkistrodon contortrix contortrix) venom.12,13 The enzyme, identified as fibrolase, is a zinc-containing metalloproteinase (1 mol of zinc per mole of enzyme) with a molecular mass of 23 kDa.13 Fibrolase possesses directacting fibrinolytic activity and does not activate plasminogen or protein C, nor does it require any bloodborne components for activity.14 The enzyme degrades the aand /3-chains of fibrin and fibrinogen. There is little degradation of the y-chain or the y-y dimer. Mecha-nisms that promote resistance of thrombi to lysis by plasminogen activator-based thrombolytic agents, including factor XIII-mediated incorporation of a2-antiplasmin into fibrin1516 or inhibition by plasminogen activator inhibitors (eg, PAI-1),17 would not apply with fibrolase, which is a metalloproteinase and is not inhibited by serine proteinase inhibitors.
Recently, southern copperhead snake venom gland mRNA has been isolated and full-length fibrolase cDNA prepared. Secretion of recombinant fibrolase (r-fibrolase) from yeast has been achieved by a plasmidmediated expression system.18 r-Fibrolase yields of 30 to 60 mg/L are obtained using a proteinase-deficient yeast strain in a defined medium containing zinc. The recombinant enzyme has been purified by a four-step procedure and shown to be identical to the natural enzyme with respect to physiochemical properties and biological activity. 18 The primary intent of this investigation was to determine if r-fibrolase, a zinc-containing metalloproteinase, could achieve thrombolysis in an experimental animal model in which a platelet-rich, occlusive arterial thrombus develops in response to a deep arterial wall injury.
We examined the thrombolytic activity of r-fibrolase and anisoylated plasminogen streptokinase activator complex (APSAC) using an experimental model of arterial thrombosis capable of exhibiting thrombolysis and reocclusion. The model used in this study is similar in principle to previously established coronary models19 but utilizes a carotid artery to minimize experimental loss due to ventricular fibrillation. In the present studies, we report that the combination of fibrolase and the 7E3 F(ab')2 monoclonal glycoprotein (GP)IIb/IIIa receptor antibody produces rapid and sustained thrombolysis in the canine carotid arterial thrombosis model system.
Methods

Animal Investigation
The studies conform to the Position of the American Heart Association on Research Animal Use adopted November 11, 1984 Electrolytic injury to the intimal surface of each carotid artery was accomplished with the use of an intravascular electrode composed of a Teflon-insulated, silver-coated copper wire. Penetration of the vessel wall by the electrode is facilitated by attaching the tip of a 25-gauge hypodermic needle to the uninsulated portion of the wire. Each intraarterial electrode is connected to the anode (+) of a dualchannel stimulator (Grass S88 stimulator and a Grass Constant Current Unit, model CCU1A, Grass Instrument Co). The cathode is attached to a distant subcutaneous site. The current delivered to each vessel is monitored continuously on separate ammeters and maintained at 300 ,A. The anodal electrode is positioned to have the uninsulated portion of the electrode in contact with the endothelial surface of the vessel. Proper positioning of the electrodes in each of the carotid arteries is confirmed by visual inspection at the end of each experiment (see Fig 1) .
Experimental Protocol Group
The anodal current is applied to the intimal surface of the carotid artery for a maximum period of 4 hours or is terminated 30 minutes after blood flow in each vessel remains stable at zero flow velocity to verify having achieved formation of a stable occlusive thrombus. Three experimental groups of six animals per group were studied. Group A consisted of animals in which the right carotid artery underwent electrolytic injury and thrombosis followed by the intra-arterial administration of APSAC 0.1 U/kg immediately proximal to the occlusive lesion. The intra-arterial administration of each compound was through a curved, 26-gauge needle attached to PE50 tubing.
Group B animals were similar to the previous group, but in addition were treated with a single intravenous dose of 0.8 mg/kg of the GPIIb/IIIa receptor antagonist, monoclonal antibody 7E3 F(ab')2. Group C animals had both carotid arteries subjected to electrolytic injury, leading to occlusive thrombus formation. Both arteries are instrumented in an identical manner, and vessel wall injury is induced simultaneously in each carotid artery. Fibrolase (4 mg/kg in a volume of 3 mL) was infused over 5 minutes proximal to the thrombus in the left carotid artery only. Sodium chloride solution (0.9%, identical rate and volume as the fibrolase infusion) was infused simultaneously, proximal to the thrombus in the right carotid artery. The opposing carotid artery was used as a control vessel to allow each dog to serve as its own control as well as minimizing the number of dogs used to complete the study. If lysis and reperfusion were achieved, 0.8 mg/kg of the GPIIb/ Illa receptor antagonist, monoclonal antibody 7E3 F(ab')2, was administered intravenously as in the previously described group B. We have demonstrated in the past that the monoclonal 7E3 antibody is capable of attenuating reocclusion after thrombolysis in similar model systems. 20, 21 Reperfusion is defined as the restoration of carotid artery blood flow velocity to 20% of baseline values. Patency is defined as measurable carotid artery blood flow velocity. Blood pressure, heart rate, and carotid artery flow velocity were monitored for 2 hours after achieving successful thrombolysis.
At the conclusion of the study protocol, each vessel segment was ligated and removed without disturbing the intravascular thrombus. The vessel segment was opened along its length, and the intact thrombus mass was lifted off the intimal surface of the vessel. The weight of the thrombus was determined with an analytical balance. After respective vessel segments had been obtained, each dog was euthanized, and a postmortem examination was performed. The chest was opened, and the pericardium was exposed for evidence of excessive blood infiltration. The appearance of the heart and surrounding pericardium appeared normal in each dog. The intestines, liver, and kidneys were examined and found to be normal in appearance. We were unable to find evidence of hemorrhaging at any site in any of the dogs that received r-fibrolase.
Hematologic Measurements
Venous blood samples (20 mL) for evaluation of platelet aggregation were withdrawn from the jugular cannula into a plastic syringe containing 3.2% sodium citrate as the anticoagulant (1:10 vol/vol, citrate/blood) at baseline, 5 minutes after thrombolysis by APSAC or fibrolase, 30 minutes after completion of the infusion of 7E3, and 2 hours after infusion of 7E3. Concentrations of red blood cells, white blood cells, hemoglobin, platelets, and the hematocrit were determined with an H-10 cell counter (Texas International Laboratories, Inc). Platelet-rich plasma (PRP), the supernatant present after centrifugation of anticoagulated whole blood at 1000 rpm for 5 minutes (140g), is diluted with platelet-poor plasma (PPP) to achieve a platelet count of 200 000/mL. PPP is prepared after the PRP is removed by centrifuging the remaining blood at 3000 rpm (2000g) for 10 minutes and discarding the bottom cell layer. Ex vivo platelet aggregation is determined by established turbidometric methods with a four-channel aggregometer (BioData-PAP-4, Bio Data Corp) by recording the increase in light transmission through a stirred suspension of PRP maintained at 37°C. Aggregation is induced with arachidonic acid (0.65 and 0.325 mmol/L) or ADP (20 and 5 ,umol/L). A 
Results
A total of 18 dogs weighing 12±1 kg were entered into the study and allocated among three groups. One dog assigned to group C was excluded because it did not meet three of the four inclusion criteria described above. Group A animals (15+2 kg, n=6) received APSAC (0.1 U/kg).
Group B animals (13+1 kg, n=6) received APSAC (0.1 U/kg) plus 7E3 F(ab')2 monoclonal antibody (0.8 mg/kg IV) 5 minutes after achieving clot lysis. Group C animals (9±1 kg, n=5) were administered r-fibrolase (4.0 mg/kg) plus 7E3 F(ab')2 monoclonal antibody (0.8 mg/kg IV) 5 minutes after thrombolysis.
Group A: APSAC-Induced Thrombolysis
The six animals in group A developed occlusive arterial thrombi in 133±12 minutes. The infusion of APSAC alone immediately proximal to the occlusive lesion lysed the thrombus in each of the six animals within a mean time of 17±3 minutes (Fig 2) . Despite the efficacy of APSAC in achieving thrombolysis, reocclusion of the carotid artery occurred in all animals within an additional 40±5 minutes (Fig 3A) . Blood flow velocity throughout the experimental protocol is summarized in Fig 4A. The mean weight of the thrombi removed partial thromboplastin time (aPTT) was determined using a from the occluded carotid arteries was 62-f-9 mg. (Fig 2) . After clot lysis was achieved, 7E3 F(ab')2 monoclonal antibody was administered and the carotid arteries remained patent in each of the six animals for the remainder of the experimental protocol (Fig 3B) . Blood flow velocity throughout the experimental protocol is summarized in Fig 4A. The carotid artery thrombi removed at the end of the study had a mean weight of 30±8 mg. Group C: r-Fibrolase-Induced Thrombolysis Plus 7E3 F(ab')2 Monoclonal Antibody Group C animals were subjected sequentially to thrombus formation in the right and left carotid arteries. The administration of 0.9% sodium chloride (3.0 mL over 5 minutes) proximal to the thrombus in the right carotid artery failed to achieve clot lysis in each of the five animals. The administration of r-fibrolase proximal to the thrombus in the left carotid artery achieved thrombolysis in all animals, within a mean time of 6±1 minutes (Fig 2) . The subsequent administration of 7E3 F(ab')2 monoclonal antibody maintained left carotid artery patency in four of the five animals so treated. One animal (No. 3) rethrombosed despite the presence of the 7E3 F(ab')2 monoclonal antibody (Fig 3C) . The results for group C are summarized graphically in Fig  4B, Tables 1 and 2 summarize the pertinent data with respect to the physiological and hematologic parameters measured in the experimental protocol. As indicated in Table 1 , there are no changes in the circulating number of erythrocytes or platelets after treatment with r-fibrolase and 7E3. The hemoglobin and hematocrit values remain relatively constant during the observation period. There was an increase in the total WBC count in blood samples removed 120 minutes after the administration of fibrolase. The significance of this, if any, is not known at present.
The mean arterial blood pressure and the heart rate were not altered after the administration of r-fibrolase. Toward the end of the experimental protocol, however, mean arterial blood pressure declined very slightly below that of the initial control value. The relation of the decrease in mean arterial pressure to the administration of r-fibrolase is not readily apparent ( Table 1) .
The administration of r-fibrolase in a total infused dose of 4 mg/kg immediately proximal to the occlusive carotid artery thrombus did not alter the aPTT (Table  2 ) from its baseline value of 111±6 versus 113±18 seconds after r-fibrolase. Ex vivo platelet reactivity in response to arachidonic acid or ADP was decreased by approximately 60% in response to both agonists. Complete inhibition of ex vivo platelet reactivity was achieved after the administration of the 7E3 monoclonal F(ab')2 antibody ( 26 The fibrin specificity of rt-PA and scu-PA in humans is not as pronounced as originally anticipated from animal models.27'28 Both rt-PA and scu-PA have relatively short half-lives due to rapid hepatic clearance, making it necessary to administer the agents by use of a loading dose followed by a continuous infusion, thereby consuming large amounts of material. Additionally, there is concern about the rapidly acting plasma inhibitor of t-PA, PAI-1,29 which is increased significantly in myocardial infarction30 and may, with other factors, predispose patients to reinfarction.31,32 Localization of PAI-1 to a thrombus by binding to fibrin could result in significant protection from degradation by plasminogen activator-type thrombolytic agents.'7 Furthermore a2-AP, which is cross-linked to fibrin by factor XIIIa, may account for a significant percentage of thrombi that are resistant to thrombolytic therapy,15 particularly in platelet-rich thrombi. 16 Investigators have attempted to overcome the abovementioned problems by enhancing thrombolytic activity and improving targeting to the thrombus. Thus, a new generation of thrombolytic agents has evolved including mutant forms of scu-PA and t-PA, hybrids between t-PA and scu-PA or between plasmin and t-PA, and synergistic combinations of t-PA and scu-PA.2228 Despite these modifications, many of which must still be subjected to vigorous preclinical and clinical testing, all current thrombolytic agents depend on the generation of plasmin through activation of plasminogen. As such, they must be directed to a site where plasminogen exists; only after activating the endogenous source of plasminogen do they become effective.
In view of the potential limitations of plasminogen activator-based thrombolytic agents, alternative interventions having potent thrombolytic activity on their own or that may act synergistically with plasminogen activators need to be evaluated. In this report, we present investigations aimed at examining a mechanism of thrombolytic therapy different from presently available therapies, which are based on the activation of plasminogen. Snake '42 The use of the carotid instead of the coronary artery has the advantage of greater yield of experimental data and where necessary allows the animal to serve as its own internal control, thereby facilitating the interpretation of results and simplifying statistical evaluation. This was an important consideration in the present study, in which r-fibrolase was in limited supply, thus accounting for the need to use relatively small animals and to administer the recombinant protein by local injection immediately proximal to the occlusive platelet-rich arterial thrombus. Furthermore, the limited supply of r-fibrolase precluded our desire to conduct dose-response studies to fully characterize the thrombolytic potential and pharmacokinetic properties of the metalloproteinase.
The study is not intended to compare r-fibrolase with other thrombolytic agents or to suggest that r-fibrolase possesses a therapeutic advantage over current therapeutic interventions used for thrombolysis. Because r-fibrolase shows enzymatic specificity for fibrin and acts independently of the need for plasmin generation, it was considered important to assess its in vivo capacity to induce arterial thrombolysis in an experimental model in which other known thrombolytic agents would achieve a comparable effect in lysing an occlusive arterial thrombus. For the latter purpose, we elected to use APSAC. As anticipated, APSAC resulted in successful thrombolysis and restoration of carotid artery blood flow in each of the animals to which it was administered. Without subsequent adjunctive therapy, however, rethrombosis followed within a relatively short time. The present results with APSAC on occlusive carotid artery thrombi and the need for adjunctive antiplatelet therapy for the prevention of rethrombosis are identical to those of a previously published report from this laboratory. 19 The present preliminary studies indicate that r-fibrolase induced rapid thrombolysis but was not able to prevent rethrombosis in this reoccluding model system without adjunctive antiplatelet therapy. Therefore, we combined the fibrinolytic enzyme with an antiplatelet agent. We used the fibrinogen receptor antagonist 7E3, a monoclonal antibody to platelet GPIIb/IIIa (fibrinogen receptor). 43 Because the GPIIb/IIIa receptor on the platelet surface represents the final common pathway for platelet aggregation, inhibition of this pathway represents an effective mechanism for inhibiting platelet aggregation independent of the inducing stimulus. That blood platelets serve as a promoter of rethrombosis in the experimental carotid artery thrombosis model was supported by studies that revealed that the platelet GPIIb/IIIa receptor antagonist SC-49992, a peptidomimetic of the fibrinogen sequence RGDF (arginyl-glycylaspartyl-phenylalanine), which blocks binding to the platelet fibrinogen receptor, prevented rethrombosis,41 as did the snake venom-derived GPIIb/IIIa receptor antagonist applaggin.42 A recent multicenter clinical trial (Thrombolysis and Angioplasty in Myocardial Infarction study, TAMI) demonstrated the efficacy of the 7E3 antibody in patients undergoing thrombolytic therapy for acute myocardial infarction. 44 Due to the limited availability of active material, the present study restricted the use of r-fibrolase to local administration immediately proximal to the site of the occlusive arterial thrombus. Although r-fibrolase enters the general circulation after dissolution of the left carotid arterial thrombus, there is minimal lysis of the contralateral thrombus (right carotid artery), presumably due to slow inactivation of the enzyme in the blood by a2-macroglobulin. Previous in vitro investigations have shown that fibrolase is inactivated by the a2-macroglobulin in a stoichiometric reaction.13 It is significant that APSAC, when studied in an identical fashion, involving local administration, like r-fibrolase also achieved lysis of the occlusive lesion. When used by local administration, neither r-fibrolase, as demon-strated in this study, nor APSAC altered the aPTT from its baseline value. 41 Willis and colleagues previously reported the purification45 and in vivo application46 of atroxase, a fibrinolytic enzyme from Crotalus atrox (western diamondback rattlesnake) venom. However, the latter studies used the intravenous route of administration for atroxase in a rat posterior vena cava thrombosis model system. The ability to monitor physiological functions and blood parameters was curtailed because of the small size of the animal species chosen for the studies.
The present study, although limited to the local application of r-fibrolase, demonstrates that local administration of the recombinant metalloproteinase lyses a carotid arterial thrombus rapidly and with no observable untoward systemic or hematologic sequelae. The enzyme in combination with antiplatelet therapy (7E3) offers a unique, safe, and specific mechanism for clot dissolution and may prove useful as a clinically efficacious alternative to, or for use in synergistic combination with, presently used thrombolytic agents.
